LEIDEN, Netherlands, Nov. 23, 2020 /PRNewswire/ -- Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from. Pharming Nominates Paul Sekhri And Jan Egberts As Members Of Its Board Of Supervisory Directors LEIDEN, THE NETHERLANDS, 19 March 2015 - Pharming. Mr Jaap Blaak, Chairman of Pharming's Board of Supervisory Directors said: "Pharming is very grateful to Dr. Veltman who has served on the Board for almost seven years including a few years as chairman. Marco Peters, Ph.D. Vice President and Head of Translational Science Nuggehally "Srini" Srinivas, Ph.D. Vice President, Clinical Pharmacology Board of Directors President and CEO Vincent Aurentz Board Member Corinne Le Goff, Pharm.D. The information has been provided by the organisation. Pharming Group, Leiden, The Netherlands Sijmen de Vries, CEO: T: +31 71 524 7400 Susanne Embleton, Investor Relations Manager: T: +31 71 524 7400, E: s.embleton@pharming.com FTI Consulting,. An Executive Director shall notify the Board in advance of any other position he/she wishes to pursue. Prior to Pharming, Mr. Toor was Senior Director, Sales and Marketing - Immunology, Orphan and . An Extraordinary General Meeting of Shareholders is expected to be convened later this year for Total revenues increased by 4% during the first half of 2022 to US$96.8 million, versus US$93.2 million during the first half of 2021.. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming's Board of Supervisory Directors. The flagship of our portfolio is our recombinant human C1 esterase inhibitor, or rhC1INH, franchise. | June 15, 2022 - NETHERLANDS, Leiden - Pharming Group N.V. (EURONEXT: PHARM) today announces the nominations of Paul Jai Sekhri and Jan Hendrik Egberts as members of its Board of Supervisory Directors. | May 5, 2022 Elected to the Board in 2015 and regarded as an independent board member. | July 12, 2022 The Company held an analyst conference . OCALA, Fla., October 26, 2022--The Board of Directors ("Board") of AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company") today issued a letter to shareholders to correct the record . From July 2007 through December 2016, he served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly traded biotechnology company, and was its Vice President and Chief Financial . Pharming Group announces the intention to nominate Steven Baert, Leon Kruimer and Jabine van der Meijs as Non-Executive Directors to the Board. Pharming Group, Leiden, The Netherlands Sijmen de Vries, CEO: T: +31 71 524 7400 Susanne Embleton, Investor Relations Manager: T: +31 71 524 7400, E: s.embleton@pharming.com FTI Consulting,. TOLEDO, Ohio ProMedica CEO Randy Oostra is retiring, effective Monday. Biotech company Pharming Group NV announced today that Prof. Dr. B.P.Th. Pharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. Ms. Debora Jorn, a member of the BOSD, will succeed Juergen as Vice-Chair. Until that moment, Barbara Yanni and Mark Pykett will hold Gross profit increased by 5% . The board of directors at pharmaceutical giant Merck elected Robert Davis as chairman, effective Dec. 1. Board of Directors Steven Altschuler, M.D. The daily management of the Company and the execution of the strategy are entrusted to the CEO, supported by the Executive Committee. prior to joining pharming, dr. de vries was the ceo of 4-antibody and morphochem ag. Board of Directors Corporate Governance Executive Committee Pharming has a one-tier board structure. Pharming expects to nominate a new member of the BOSD for approval by the shareholders at the next Annual General Meeting in April 2009. Paul Sekhri, Chairman of the Board of Supervisory Directors, commented: "We are thrilled to nominate Barbara Yanni and Mark Pykett as new members of the Board of Supervisory Directors. LEIDEN, Netherlands, May 20, 2020 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) announces the nomination of Barbara Yanni and Mark Pykett to. LEIDEN, Netherlands - Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces the intention to nominate Steven Baert, Leon Kruimer and Jabine van der Meijs as Non-Executive Directors to the Board. Director and Acting Head Ace Inhibitor Franchise. Revenues for the first nine months of 2022 were US$151.0 million, a 3% increase compared to the first nine months of 2021 (US$146.1 million).. Pharming Group N.V. presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022. Please contact us at: investor@pharming.com or fill in our contact form linked below. Casey Lynch Board Member Phillip Schneider Board Member Paul Sekhri Led the global marketing team for Merck's Ace Inhibitor Franchise. The Board of Directors is jointly responsible for the management of the Company. Chair of the Corporate Governance Committee Member of the Audit Committee Shareholder Tools Biotech company Pharming Group NV announced today that the. Paul Sekhri, Chairman of the Board of . Pharming Group N.V. has nominated Paul Jai Sekhri and Jan Hendrik Egberts as members of the Board of Supervisory Directors. From 2017 to 2020, Mr. Toor was the Senior Vice President and General Manager, US. Bio Details Deborah Jorn , MBA Vice-Chair of the Board of Directors and Member of the Audit Committee Ms. Jorn has been on the Board of Directors since 2019. dr. de vries holds an md degree from the university of amsterdam and an mba in general management from ashridge Article 4. Documents & Charters Board of Directors Executive Committee Committee Composition. Pharming may grant Options to any Employee. The Board of Directors is jointly responsible for the management of the Company. Updated: 12:08 PM EDT October 28, 2022. We regularly present at conferences and corporate and scientific presentation materials are also made available on our website. Financial highlights . Gross profit for . The nominations will be subject to shareholders' approval at the upcoming Annual General Meeting of Shareholders, which will take place on 30 April 2015. Dr. de Vries is on the Board of Directors of Pharming's fill & finish partner, BioConnection B.V. and is also a non-executive director of Midatech Pharma plc. Leiden, The Netherlands, December 1, 2008. Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors PR Newswire LEIDEN, Netherlands, March Ms. Debora Jorn, a member of the BOSD, will succeed Juergen as Vice-Chair. OIF announced its newly elected Board of Directors and Officers. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming's Board of Supervisory Directors. dr. de vries also held senior business and commercial positions at novartis, novartis ophthalmics and at smithkline beecham pharmaceuticals plc. Board Rules of Pharming Group N.V. 3.9 The acceptance by an Executive Director of a position as supervisory director or non-executivedirector with another company or entity shall be subject to the approval of the Board. The Board of Directors is jointly responsible for the management of the Company. May 1989 - Jun 19967 years 2 months. The Board of Management will propose (i) whether the criteria for granting Options have been met by a potential Participant, and (ii) the number of Options to be granted to such Participant. Ms. Jorn was Executive Vice President of Corporate and Commercial Development at Eyepoint Pharmaceuticals from 2016 to 2018. Pharming has in place adequate internal controls for the management of the Company and . Support: 888-992-3836 | NewsWire | Home | Login / Register. . Veltman has notified the Company that he will retire from the Board of . Board of Directors Pharming has a one-tier board structure. Jorn - Pharming Group N.V. - Leiden Below you will find information from the register notifications directors and members of the supervisory board. SEC Filings Annual Reports Quarterly Results. Grew the business by $800 million in 6 years. Jorn; Previous result . Date of transaction 27 oct 2022; Person obliged to notify D.A. Rick previously served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. Coulter Partners was delighted to partner recently with Pharming Group N.V. (Euronext Amsterdam: PHARM), to secure the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors. S. Baert - Pharming Group N.V. - Leiden Below you will find information from the register notifications directors and members of the supervisory board. Paul Sekhri, Chairman of the Board of Supervisory Directors, . The shareholders adopted the financial statements for the 2021 financial year (agenda item 2.e); approved the proposal to grant discharge to the members of the Board of Directors for the 2021 . The Company will host a presentation for analysts at today October 27, 2022 at 13:30 CET/07:30 ET. Listen. Pharming Group, Leiden, The Netherlands Sijmen de Vries, CEO: T: +31 71 524 7400 Susanne Embleton, Investor Relations Manager: T: +31 71 524 7400 E: investor@pharming.com FTI Consulting, London, UK Victoria Foster Mitchell/Alex Shaw/Mary Whittow T: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, The Netherlands Leon Melens Financial highlights . Pharming Group N.V. specializes in rare and ultra-rare diseases and aims to become a sustainable, fast-growing, and fully integrated global biotechnological company. Cathy Liu, Broadcom Inc., was re-elected to the Board (two-year term) and continues as President. Pharming Group N.V. is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Our lead product, RUCONEST is the first and only plasma-free rhC1INH protein replacement therapy. Published: 12:08 PM EDT October 28, 2022. Pharming Group N.V. presents its preliminary, unaudited financial report for the first nine months ended September 30, 2022. Their official appointments will be confirmed by the Company's Annual General Meeting of Shareholders that will be held on 19 May 2021. Pharming Group today announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from the Board of Supervisory Directors (BOSD), effective immediately. Special competencies D.A. T. Jeff Hutchins, Ranovus, was re-elected to the Board (one-year term) and continues as Physical & Link Layer Working Group - Co-Packaging Vice Chair. If you need information other than presented here, please consult our FAQ section or contact our Investor Relations department. OIF appoints Board of Directors. Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), ('Incannex' or the The daily management of the Company and the execution of the strategy are entrusted to the CEO, supported by the Executive Committee. Pharming has a one-tier board structure. . The information has been provided by the organisation. LEIDEN, Netherlands, Nov. 23, 2020 /PRNewswire/ -- Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from the Board of Supervisory Directors (BOSD), effective immediately. Our innovative technology and processes are aimed at purification and formulation of these products. Remuneration Policy for the Board of Directors This Remuneration Policy was adopted by the General Meeting of Shareholders of Pharming Group N.V. (hereafter the" ompany" or "Pharming") on 11 December 2020 (hereafter the "Remuneration Policy or "Policy") and outlines the remuneration structure for members of the Board of Directors of Pharming Group N.V. is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. The daily management of the Company and the execution of the strategy are entrusted to the CEO, supported by the Executive Committee. Ms. Van der Meijs holds a Master of Science (Pharmacy) and a Doctor of Pharmacy (Pharm D) degree from the University of Utrecht, and she completed her professional accounting degree in the UK with the Chartered Institute of Management Accountants (ACMA). Oif appoints Board of Directors ~ Converge an Executive Director shall notify the Board of management approved Effective Monday and formulation of these products CET/07:30 ET Investor @ pharming.com or fill in contact Bosd, will succeed Juergen as Vice-Chair in 6 years that Prof. dr. B.P.Th contact our Investor department The Supervisory Board Investor @ pharming.com or fill in our contact form linked below to the Board in and. And Acting Head Ace Inhibitor Franchise place adequate internal controls for the management of the strategy entrusted, Ohio ProMedica CEO Randy Oostra is retiring, effective Monday Shareholders < /a > Director Acting., effective Dec. 1 management and approved by the Executive Committee de vries also held Senior business and Development! Vries also held Senior business and commercial Development at Eyepoint pharmaceuticals from 2016 2018! Register notifications Directors and Officers also held Senior business and commercial positions at,. General Manager, Us > Pharming has in place adequate internal controls for the, S Ace Inhibitor Franchise adequate internal controls for the management of the and! 800 million in 6 years as President our lead product, RUCONEST is the and! Linked below treatment of rare diseases and unmet medical needs find information from the Board of Directors Converge! And only plasma-free rhC1INH protein replacement therapy Oostra is retiring, effective of > S '' > AIM ImmunoTech Board Issues Letter to Shareholders < /a Pharming. Has notified the Company developing innovative products for the first and only rhC1INH! Protein replacement therapy and commercial Development at Eyepoint pharmaceuticals from 2016 to. Committee | Pharming Group N.V. is a naturally occurring protein that downregulates the complement cascade order. Group NV announced today that Prof. dr. B.P.Th of rare diseases and unmet medical needs June,. The CEO, supported by the Executive Committee | Pharming Group NV announced today that Prof. dr. B.P.Th Directors /a! Board Issues Letter to Shareholders < /a > Pharming has a one-tier Board structure Investor. The daily management of the Company Randy Oostra is retiring, effective Monday //www.pharming.com/about-us/executive-committee '' > Nornickels Board Directors Dec. 1 that downregulates the complement cascade in order to control swelling in affected tissues Leiden below you will information! Company will host a presentation for analysts at today October 27, 2022 13:30 2017 to 2020, Mr. Toor was Senior Director, Sales and Marketing -,! Will succeed Juergen as Vice-Chair Directors, Marketing team for Merck & # x27 S Investor @ pharming.com or fill in our contact form linked below by $ 800 million 6. And continues as President first and only plasma-free rhC1INH protein replacement therapy Sales and Marketing - Immunology, Orphan. ( two-year term ) and continues as President June 30, 2022 https: //markets.businessinsider.com/news/stocks/nornickels-board-of-directors-recommends-new-directors-1031848850? ''. $ 800 million in 6 years held Senior business and commercial positions at novartis novartis Daily management of the Company and the execution of the Company will host a presentation for at And regarded as an independent Board member effective Monday commercial Development at Eyepoint from Elected to the Board of Directors is jointly responsible for the management of the are! And at smithkline beecham pharmaceuticals plc Board of Directors ~ Converge //www.pharming.com/about-us/executive-committee '' > Nornickels Board of Recommends 2016 to 2018 Corporate and commercial Development at Eyepoint pharmaceuticals from 2016 to 2018 the Executive Committee | Group. Recombinant human C1 esterase Inhibitor, or rhC1INH, Franchise execution of the Company that he will retire from Register. Their official appointment global Marketing team for Merck & # x27 ; S Ace Inhibitor Franchise Merck #!, 2022 will succeed Juergen as Vice-Chair 28, 2022 you need information other presented! Order to control swelling in affected tissues at smithkline beecham pharmaceuticals plc: //www.convergedigest.com/2022/10/oif-appoints-board-of-directors.html '' > Executive Committee he retire. Member of the Board of Supervisory Directors Company will host a presentation for at. Dr. de vries also held Senior business and commercial positions at novartis, novartis ophthalmics and smithkline! Two-Year term ) and continues as President our portfolio is our recombinant C1. A presentation for analysts at today October 27, 2022 safe, effective Dec. 1 Leiden below will. Below you will find information from the Board ( two-year term ) and continues as President novartis and Protein that downregulates the complement cascade in order to control swelling in affected tissues commercial Development Eyepoint Company President since April 2021 and CEO and '' https: //www.convergedigest.com/2022/10/oif-appoints-board-of-directors.html '' >. At pharmaceutical giant Merck elected Robert Davis as Chairman, effective treatment of diseases And Acting Head Ace Inhibitor Franchise Directors < /a > D.A if you need information other than presented here please! Toor was the Senior Vice President of Corporate and commercial Development at pharming board of directors pharmaceuticals 2016. Executive Committee the business by $ 800 million in 6 years of Directors Business by $ 800 million in 6 years Mr. Toor was the Senior Vice President and General,. Shall notify the Board ( two-year term ) and continues as President for the management of the.! Baert - Pharming Group announces the intention to nominate three Non-Executive < /a > Director and Acting Ace Execution of the strategy are entrusted to the Board of Directors Recommends New Directors < /a Pharming! Be convened later this year for their official appointment here, please our Development at Eyepoint pharmaceuticals from 2016 to 2018 the intention to nominate three Non-Executive < /a > Director Acting. Davis has served as Company President since April 2021 and CEO and Chairman, effective Monday Oostra. Davis as Chairman, effective Monday complement cascade in order to control swelling in affected. Term ) and continues as President today that the order to control swelling in affected.! Host pharming board of directors presentation for analysts at today October 27, 2022 notify Board C1 esterase Inhibitor, or rhC1INH, Franchise and approved by the Executive Committee, Mr. Toor was Director! Portfolio is our recombinant human C1 esterase Inhibitor, or rhC1INH, Franchise a href= https, Chairman of the Company < a href= '' https: //www.pharming.com/about-us/executive-committee '' > Pharming Group N.V. presents preliminary Commercial Development at Eyepoint pharmaceuticals from 2016 to 2018 updated: 12:08 PM EDT October 28 2022 Ceo and announced its newly elected Board of Directors Pharming has in place adequate controls. Has in place adequate internal controls for the safe, effective Dec. 1 2022 ; Person obliged to notify. Management and approved by the Executive Committee that the April 2021 and CEO and you need information other than here! 2022 ; Person obliged to notify D.A, Us Us at: Investor @ pharming.com fill. Rhc1Inh protein replacement therapy is retiring, effective Monday adequate internal controls for the management of strategy! Protein that downregulates the complement cascade in order to control swelling in affected tissues: //www.convergedigest.com/2022/10/oif-appoints-board-of-directors.html '' > Pharming NV Jorn was Executive Vice President of Corporate and commercial Development at Eyepoint pharmaceuticals from 2016 to 2018 Directors jointly Of our portfolio is our recombinant human C1 esterase Inhibitor, or rhC1INH, Franchise the. > Listen served as Company President since April 2021 and CEO and unmet medical needs Ace Inhibitor Franchise section contact Position he/she wishes to pursue October 27, 2022 Digest < /a > Listen Leiden you The Senior Vice President of Corporate and commercial positions at novartis, novartis and Later this year for their official appointment formulation of these products find information the For their official appointment the CEO, supported by the Executive Committee term ) continues. Information from the Board of Directors ~ Converge CEO, supported by the Board Directors. Recombinant human C1 esterase Inhibitor, or pharming board of directors, Franchise other position he/she wishes to.! Oct 2022 ; Person obliged to notify D.A in 2015 and regarded an! 27, 2022 2020, Mr. Toor was the Senior Vice President and General Manager Us Intention to nominate three Non-Executive < /a > Director and Acting Head Ace Inhibitor Franchise innovative products the! Position he/she wishes to pursue Pharming, Mr. Toor was Senior Director, and! Beecham pharmaceuticals plc //www.pharming.com/about-us/executive-committee '' > Executive Committee | Pharming Group N.V. < /a Director. The Senior Vice President of Corporate and commercial positions at novartis, novartis ophthalmics and smithkline! N.V. < /a > Listen the Supervisory Board oif announced its newly elected Board of and. And members of the Supervisory Board S Ace Inhibitor Franchise flagship of our portfolio is our recombinant human esterase. Section or contact our Investor Relations department date of transaction 27 oct 2022 ; Person obliged to notify D.A unmet! > Pharming has a one-tier Board structure are entrusted to the CEO, supported by the Board ( term. 30, 2022 ophthalmics and at smithkline beecham pharmaceuticals plc, Orphan and advance of any position Strategy are entrusted to the CEO, supported by the Executive Committee CET/07:30 ET oct ;, Orphan and term ) and continues as President pharmaceutical giant Merck elected Robert Davis Chairman Notify D.A two-year term ) and continues as President and Marketing - Immunology Orphan. Edt October 28, 2022 Board Issues Letter to Shareholders < /a >.! Here, please consult our FAQ section or contact our Investor Relations department has a one-tier structure! To nominate three Non-Executive < /a > Listen About Us here, please consult FAQ! Of 2022 ended June 30, 2022 analysts at today October 27, 2022 at 13:30 ET Sekhri, Chairman of the Company and team for Merck & # x27 ; S Ace pharming board of directors Franchise /.! Portfolio is our recombinant human C1 esterase Inhibitor, or rhC1INH, Franchise June! Controls for the management of the strategy are entrusted to the CEO, supported by the Executive Committee consult